Rus En Es
Main / Company's news / GEROPHARM’s Expertise in Clinical Studies of Insulin Biosimilars is Recognised Internationally

GEROPHARM’s Expertise in Clinical Studies of Insulin Biosimilars is Recognised Internationally

21 February 2020

On February 19 to 22 in Madrid, Spain, one of the key European scientific events takes place, the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), and GEROPHARM experts give presentations on clinical studies of insulin analogue biosimilars.

ATTD is a well-recognised platform where renowned international experts discuss innovative solutions in diabetes mellitus treatment. The annual event is attended by speakers from USA, Israel, Slovenia, United Kingdom, Sweden, Spain, Germany, Belgium, UAE, Denmark, the Netherlands, Poland, Serbia, France, Canada, Italy, etc.

GEROPHARM attends the forum for the first time. Anna Mosikyan, Medical Advisor, GEROPHARM, gave a presentation on the results of pharmacokinetics, pharmacodynamics, and safety (immunogenicity) studies of insulin glargine (RinGlar) produced by the company.

The presentation abstract will be published in the specialised international journal Diabetes Technology & Therapeutics. The article will be also available on the company’s website.

The information on the posters, however, is already available at the links below:

  1. Results of insulin glargine pharmacokinetics and pharmacodynamics study
  2. Results of insulin glargine immunogenicity study
  3. Concentration of anti-insulin antibodies in T1D patients taking different insulins

You are a health care professional?

Go up